Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients' selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vision of a single biomarker is somewhat naïve and imprecise, given that immunotherapy does not follow the rules that we have experienced in the past for targeted therapies. On the other hand, additional immune-related biomarkers that are reliable in real-life clinical practice remain to be identified. Recently, the immune-checkpoint blockade has been approved in the US irrespective of the tumor site of origin. Further histology-agnostic approvals, coupled with with tumor-specific companion diagnostics and guidelines, are expected in this field. In addition, immune-related biomarkers can also have a significant prognostic value. In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer.

Targeting immune-related biological processes in solid tumors : we do need biomarkers / F. Pagni, E. Guerini-Rocco, A.M. Schultheis, G. Grazia, E. Rijavec, M. Ghidini, G. Lopez, K. Venetis, G.A. Croci, U. Malapelle, N. Fusco. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 20:21(2019), pp. 5452.1-5452.18. [10.3390/ijms20215452]

Targeting immune-related biological processes in solid tumors : we do need biomarkers

E. Guerini-Rocco;G. Grazia;M. Ghidini;G. Lopez;K. Venetis;G.A. Croci;N. Fusco
Ultimo
2019

Abstract

Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients' selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vision of a single biomarker is somewhat naïve and imprecise, given that immunotherapy does not follow the rules that we have experienced in the past for targeted therapies. On the other hand, additional immune-related biomarkers that are reliable in real-life clinical practice remain to be identified. Recently, the immune-checkpoint blockade has been approved in the US irrespective of the tumor site of origin. Further histology-agnostic approvals, coupled with with tumor-specific companion diagnostics and guidelines, are expected in this field. In addition, immune-related biomarkers can also have a significant prognostic value. In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer.
Biomarkers; Breast cancer; Breast cancer; Cancer; Gastrointestinal tract cancer; Head and neck cancer; Immunoediting; Immunotherapy; Lung cancer; Melanoma; Renal cell carcinoma; Urothelial cancer
Settore MED/08 - Anatomia Patologica
Settore MED/06 - Oncologia Medica
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
[2019] [Int J Mol Sci] Targeting immune-related biological processes in solid tumors_ we do need biomarkers.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/690981
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 46
social impact